METAVIA INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
METAVIA INC. (MTVA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $2.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- METAVIA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $3.45M.
- METAVIA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$4.83M.
- METAVIA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$6.45M.
- METAVIA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$2.55M.
- METAVIA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$5.74M.
- METAVIA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$6.42M.
- METAVIA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$10.93M, a 164.38% decline from fiscal 2022.
- METAVIA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $16.98M, a 169.22% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.36M 10-Q · filed 2026-08-06 | |||||
| 2026-03-31 | $3.45M 10-Q · filed 2026-05-14 | |||||
| 2025-12-31 | -$5.74M 10-K · filed 2026-03-26 | |||||
| 2025-09-30 | -$1.74M 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | $1.57M 10-Q · filed 2026-08-06 | |||||
| 2025-03-31 | -$4.83M 10-Q · filed 2026-05-14 | |||||
| 2024-12-31 | -$6.42M 10-K · filed 2026-03-26 | |||||
| 2024-09-30 | -$766.00K 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | $5.50M 10-Q · filed 2025-08-07 | |||||
| 2024-03-31 | -$6.45M 10-Q · filed 2025-05-14 | |||||
| 2023-12-31 | -$10.93M 10-K · filed 2025-03-20 | |||||
| 2023-09-30 | -$7.53M 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | -$4.68M 10-Q · filed 2024-08-14 | |||||
| 2023-03-31 | -$2.55M 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | $16.98M 10-K · filed 2024-03-28 | |||||
| 2022-09-30 | -$10.03M 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | -$7.54M 10-Q · filed 2023-08-09 | |||||
| 2022-03-31 | -$4.83M 10-Q · filed 2023-05-12 | |||||
| 2021-12-31 | $6.31M 10-K · filed 2023-03-30 | |||||
| 2021-09-30 | -$3.10M 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$567.00K 10-Q · filed 2022-08-12 | |||||
| 2021-03-31 | $2.95M 10-Q · filed 2022-05-13 | |||||
| 2020-12-31 | -$3.84M 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | -$1.56M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $394.00K 10-Q · filed 2021-08-16 | |||||
| 2020-03-31 | -$4.09M 10-Q · filed 2021-05-17 | |||||
| 2019-12-31 | $11.07M 10-K · filed 2021-04-15 | |||||
| 2019-09-30 | $18.29M 10-Q · filed 2020-11-13 | -$17.08M 10-Q · filed 2019-11-08 | ||||
| 2019-06-30 | $21.73M 10-Q · filed 2020-08-11 | -$15.30M 10-Q · filed 2019-08-09 | ||||
| 2019-03-31 | -$1.22M 10-Q · filed 2020-05-20 | |||||
| 2018-12-31 | $2.79M 10-K · filed 2020-03-30 | |||||
| 2018-09-30 | $5.33M 10-Q · filed 2019-11-08 | |||||
| 2018-06-30 | $9.57M 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |